China Unveils Trade Rules to Block US Derisking Push
Get the Geopolitics newsletter
Daily geopolitics — wars, elections, sanctions, the diplomatic moves that move markets. Free.
- China rolled out new trade regulations in April targeting foreign entities that "suspend normal transactions" with Chinese citizens or organizations, announced weeks before Trump's May 14-15 summit with Xi Jinping.
- The rules establish a legal framework for investigating and punishing companies that reduce sourcing from China, with a second set of regulations published days later targeting firms that comply with US extraterritorial sanctions.
- The Trump administration has offered no public response; the White House, Treasury Department, and Office of the US Trade Representative all declined to comment substantively, marking a "departure from trade brinkmanship" compared to the October Busan summit.
- The American Chamber of Commerce in China warned that China could cut purchases from foreign firms with little consequence while foreign companies face Chinese investigations for reducing dependence.
- FDD's Craig Singleton said the US silence "risks signalling weakness" and warned that unaddressed rules would "normalise supply chain coercion," while Rhodium Group's Reva Goujon said China is "clearly in a much more emboldened position."
- US pharmaceutical companies that have moved some production to India and other countries are among those potentially exposed, facing possible investment and import/export bans under the new framework.
Why it matters: China's new rules directly undercut Trump's "derisk" agenda by penalizing the exact supply chain shifts the administration has been pushing in critical minerals and medicines. With the Trump-Xi summit days away and US officials in "listening mode," American firms that have moved production to India now face new Chinese investigation and ban risks, giving Beijing leverage to lock in corporate dependence and test how much trade-war pause the White House wants to preserve.
